TABLE OF CONTENTS

SPECIAL COLLECTION: HONORING PAUL F. ENGSTROM, MD, CHAMPION OF CANCER PREVENTION

215 Honoring Paul F. Engstrom, MD: A Pioneer of Cancer Prevention
    Margie L. Clapper and Carolyn Y. Fang

219 Navigating the Intersection between Genomic Research and Clinical Practice
    Mary B. Daly

223 A Multi-level Model to Understand Cervical Cancer Disparities in Appalachia
    Electra D. Paskett, Michael L. Pennell, Mack T. Ruffin, Christopher M. Weghorst, Bo Lu, Erin M. Hade, Juan Peng, Brittany M. Bernardo, and Mary Ellen Wewers

229 Dysplastic Aberrant Crypt Foci: Biomarkers of Early Colorectal Neoplasia and Response to Preventive Intervention
    Margie L. Clapper, Wen-Chi L. Chang, and Harry S. Cooper

241 Reducing Ovarian Cancer Mortality Through Early Detection: Approaches Using Circulating Biomarkers
    Camille V. Trinidad, Ashley L. Tettlow, Leonidas E. Bantis, and Andrew K. Godwin

253 Addressing Disparities in Cancer Screening among U.S. Immigrants: Progress and Opportunities
    Carolyn Y. Fang and Camille C. Ragin

261 The Use of the Nicotine Metabolite Ratio as a Biomarker to Personalize Smoking Cessation Treatment: Current Evidence and Future Directions
    Scott D. Siegel, Caryn Lerman, Alex Flitter, and Robert A. Schnoll

RESEARCH ARTICLES

273 Combination of Erlotinib and Naproxen Employing Pulsatile or Intermittent Dosing Profoundly Inhibits Urinary Bladder Cancers
    Altaf Mohammed, Mark Steven Miller, Ronald A. Lubet, Chen S. Suen, Shizuko Sei, Robert H. Shoemaker, Margaret M. Juliana, Fariba L. Moeinpour, and Clinton J. Grubbs

283 Use of Biomarker Modulation in Normal Mammary Epithelium as a Correlate for Efficacy of Chemopreventive Agents Against Chemically Induced Cancers
    Ronald A. Lubet, Brandy M. Heckman-Stoddard, Jennifer T. Fox, Fariba Moeinpour, M. Margaret Juliana, Robert H. Shoemaker, and Clinton J. Grubbs

291 A Multi-Institutional Cohort of Therapy-Associated Polyposis in Childhood and Young Adulthood Cancer Survivors
    Leah H. Biller, Chinedu Ukaegbu, Tara G. Dingra, Carol A. Burke, Yana Chertock, Anuradha Chittenden, James M. Church, Erika S. Koepp, Brandie H. Leach, Elana Levinson, Ramona M. Lim, Megan Lutz, Erin Salo-Mullen, Rania Sheikh, Gregory Idos, Fay Kastrinos, Elena Stoffel, Jennifer M. Weiss, Michael J. Hall, Matthew F. Kalady, Zofia K. Stadler, Sapna Syngal, and Matthew B. Yurgelun

299 The Quality of Pap Smears from the Brazilian Cervical Cancer Screening Program According to the Human Development Index
    Ricardo Filipe Alves Costa, Adhemar Longatto-Filho, Fabiana de Lima Vazquez, Céline Pinheiro, Luiz Carlos Zeferino, and José Humberto Tavares Guerreiro Fregnani

309 Economic Evaluation of Tailored Web versus Tailored Telephone-Based Interventions to Increase Colorectal Cancer Screening among Women
    David R. Lairson, Tong Han Chung, Danneng Huang, Timothy E. Stump, Patrick O. Monahan, Shannon M. Christy, Susan M. Rawl, and Victoria L. Champion
Inflammation and epidermal growth factor receptor (EGFR) signaling dysregulation play an important role in urinary bladder cancer development. Non-steroidal anti-inflammatory drugs (NSAIDs) and EGFR inhibitors may block bladder tumorigenesis. However, daily dosing of either NSAIDs or EGFR inhibitors can cause gastrointestinal ulceration and acneiform rash, respectively, limiting their continuous use in a clinical prevention setting. To explore the utility of alternative dosing and scheduling of combination regimens, Mohammed and colleagues (in a study beginning on page 273) evaluated chemopreventive efficacy of pulsatile dosing of EGFR inhibitor erlotinib (once/week) combined with intermittent (3 weeks on/off) or continuous low doses of the NSAID naproxen in the OH-BBN induced rat bladder cancer model. All combination regimens tested, including late intervention with intermittent low-dose naproxen and weekly erlotinib combination, exerted robust antitumor effects. These findings demonstrate that significant chemopreventive efficacy could be achieved with alternative intervention designs to reduce the toxicity of agents, and that starting the combination treatments at the time microscopic tumors were present still conferred the efficacy. The photograph on the cover shows a typical histological image of transitional cell carcinoma in the urinary bladder of an untreated female Fischer-344 rat exposed to the carcinogen OH-BBN.